SEC Form 10-K filed by ImageneBio Inc.
$IMA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/25/2025 | $2.00 | Underperform | Wedbush |
| 10/24/2025 | $30.00 | Outperform | Leerink Partners |
Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00
Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00
3 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
4 - ImageneBio, Inc. (0001835579) (Issuer)
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience.The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regim
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targe
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo
4 - ImageneBio, Inc. (0001835579) (Issuer)
S-8 - ImageneBio, Inc. (0001835579) (Filer)
10-K - ImageneBio, Inc. (0001835579) (Filer)
8-K - ImageneBio, Inc. (0001835579) (Filer)
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo